Atezolizumab Plus Bevacizumab vs Sorafenib for Unresectable Hepatocellular Carcinoma: Results From Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial

Introduction The efficacy of systemic first-line treatments in older adults with unresectable hepatocellular carcinoma (HCC) has not been well-studied. We compared the safety and efficacy of atezolizumab plus bevacizumab vs sorafenib as a first-line treatment in younger vs older patients with unresectable HCC. Methods This global, phase 3, open-label, randomized clinical trial (IMbrave150) recruited patients aged ≥18 years with locally advanced metastatic or unresectable HCC, an Eastern Cooperative Oncology Group performance status score of 0 or 1, and Child-Pugh class A liver function who had not previously received systemic therapy for liver cancer. Patients received either 1200 mg atezolizumab plus 15 m g/kg bevacizumab intravenously every 3 weeks or 400 mg sorafenib orally twice daily until loss of clinical benefit or unacceptable toxicity. Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary outcomes were incidence of adverse events and time to deterioration of patient-reported outcomes (PROs). This subgroup analysis evaluated safety and efficacy endpoints in patients
Source: Liver Cancer - Category: Cancer & Oncology Source Type: research